# Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Study · id `cardio:ct-nct03115112` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03115112](<https://clinicaltrials.gov/study/NCT03115112>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03115112

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 386 participants.

## Technical summary

Registry record NCT03115112. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-12 (actual); primary completion 2018-10-31 (actual). Results posted on 2021-06-04.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 386 participants (enrolled count; ClinicalTrials.gov record NCT03115112, source copy `cardio:ctgov-nct03115112-2021-06-22`, retrieved 2026-10-26)
- Started: 2017-10-12 (actual) (ClinicalTrials.gov record NCT03115112, source copy `cardio:ctgov-nct03115112-2021-06-22`, retrieved 2026-10-26)
- Primary completion: 2018-10-31 (actual) (ClinicalTrials.gov record NCT03115112, source copy `cardio:ctgov-nct03115112-2021-06-22`, retrieved 2026-10-26)
- Completion: 2018-10-31 (actual) (ClinicalTrials.gov record NCT03115112, source copy `cardio:ctgov-nct03115112-2021-06-22`, retrieved 2026-10-26)
- Results first posted: 2021-06-04 (ClinicalTrials.gov record NCT03115112, source copy `cardio:ctgov-nct03115112-2021-06-22`, retrieved 2026-10-26)
- Countries: United States; Czechia; Hungary; Japan; Poland; Spain (ClinicalTrials.gov record NCT03115112, source copy `cardio:ctgov-nct03115112-2021-06-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03115112-2021-06-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Bexagliflozin
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Placebo for sitagliptin
- Intervention (Drug): Placebo for bexagliflozin
- Lead sponsor: Theracos
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Theracos (`cardio:org-theracos`)

## Provenance

Content hash: e2e8b4711a8980704d27f2e6b28e7421a3ff7cfd5b6095279857954fd58b9490
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
